




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/991,936	11/21/2001	Kevin S. Brandt	FC-6-C4

Heska Corporation
1613 Prospect Park
Fort Collins, CO 80525



COPY

COPY OF PAPERS
ORIGINALLY FILED

CONFIRMATION NO. 7792

FORMALITIES LETTER



OC00000007177265

Date Mailed: 12/10/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



COPY OF PAPERS
ORIGINALLY FILED



Heska Corporation
Intellectual Property Dept.
1613 Prospect Parkway
Fort Collins, CO 80525

'01 DEC 10 RCU'

25



COPY

Docketed

DATE: November 21, 2001
APPLICANT: Kevin S. Brandt, Patrick J. Gaines, Dan T.
Stinchcomb, Nancy Wisnewski
SERIAL NO.: not yet assigned
ATTY. FILE NO.: FC-6-C4
TITLE: "FLEA HEAD, NERVE CORD, HINDGUT AND
MALPIGHIAN TUBULE NUCLEIC ACID
MOLECULES, PROTEINS AND USES THEREOF"

RECEIPT IS HEREBY ACKNOWLEDGED OF: Certificate of
Mailing by Express Mail; Utility Patent Application Transmittal
(Small Entity); Preliminary Amendment; Verified Statement
(Declaration) Claiming Small Entity Status - Small Business
Concern; Power of Attorney; 248 pages of specification, claims
and abstract; 776 pages of sequence listing; deposited with the
U.S. Postal Service as "Post Office to Addressee Express Mail"
label no. EL344801697US this date.
Also enclosed is a copy of Declaration from priority case.

